New WCM-Q research probes molecular processes that cause diabetes

Researchers at Weill Cornell Medicine-Qatar (WCM-Q) have made new discoveries about the complex metabolic and genetic processes which drive the formation of new fat cells, shedding light on the possible causes of obesity and its complications, such as inflammation and metabolic diseases like type 2 diabetes.

Using Crispr gene editing technology, the researchers demonstrated that a protein called UHRF1 plays a key role in the regulation of the formation of new fat cells, known as adipogenesis.

They also showed that the UHRF1 protein suppresses fibrosis, which is the hardening or scarring of bodily tissues and a characteristic of many inflammatory illnesses.

Increased fibrosis in the adipose tissue is a hallmark of insulin resistance and adipose tissue dysfunction.

Working with mouse cells in the laboratory, the researchers used Crispr to delete a gene that codes for the production of the UHRF1 protein.

They then demonstrated that these UHRF1-knockout cells showed significantly reduced levels of adipogenesis, a process of differentiating fat cells from their precursors.

The WCM-Q researchers went a step further by using the college’s advanced genomics and bioinformatics analysis tools to identify the altered molecular and cellular pathways involved in adipogenesis regulation, which are impacted by UHRF1.

This led to the researchers successfully identifying elevated levels of the cytokine TGFβ (transforming growth factor beta) and its downstream targets.

TGFβ is a fibrosis regulator.

Additionally, when TGFβ goes awry, it is known to drive the transformation of normal cells into aggressively growing cancer cells.

The researchers also demonstrated that UHRF1-depleted cells show increased expression and secretion of TGFβ as well as Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB).

They also provided evidence that treating cells with GPNMB led to a reduction in adipogenesis and an increase in TGFβ levels and signaling.

Elevated TGFβ in obese subjects is linked to a poor obesity complication outcome, with symptoms including hypertension, diabetes, inflammation, and adipose tissue fibrosis.

Regulation of TGFβ is important because it is critical for many metabolic processes.

After demonstrating the results in experiments on mouse genes, the team confirmed the same findings in tests on human cells.

This new discovery provides greater understanding of how the metabolism functions, as well as suggesting potential targets for the creation of new drug therapies for the clinical management of obesity and associated metabolic disorders.

WCM-Q’s Dr Muneera Vakayil, postdoctoral associate in microbiology & immunology, is the lead author of the paper, which has been published in *Scientific Reports, a Nature Group publication.

“This has been a really exciting piece of research because it presents potential therapeutic targets for type 2 diabetes,” she said. “We are looking forward to conducting more research in this area to further improve our understanding of the processes which drive metabolic disorders.”

The publication of the paper marks a significant career milestone for Dr Vakayil as it forms part of her PhD, which she pursued at Hamad Bin Khalifa University.

Other WCM-Q researchers who worked on the paper were assistant professor of microbiology and immunology Dr Nayef Mazloum, postdoctoral associate in microbiology and immunology Dr Aisha Madani al-Malki, research associate in microbiology and immunology Dr Yasser Majeed, senior research specialist Dr Shahina Hayat, senior bioinformatics data analyst Shameem Yonuskunju, genomics core assistant director Yasmin Ali Mohamoud, associate professor of genetic medicine Dr Joel Malek, and Dr Karsten Suhre, professor of physiology and biophysics and director of the bioinformatics core.

Maha V Agha of the Translational Research Institute at Hamad Medical Corporation also contributed to the paper.

The research was supported by the WCM-Q's Biomedical Research Programme, supported by Qatar Foundation.